BOULDER, Colo. (AP) _ Array BioPharma Inc. (ARRY) on Wednesday reported a loss of $35.3 million in its fiscal third quarter.
The Boulder, Colorado-based company said it had a loss of 21 cents per share.
The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.
The drug developer posted revenue of $33.3 million in the period, also falling short of Street forecasts. Four analysts surveyed by Zacks expected $47 million.
Array BioPharma shares have decreased 20 percent since the beginning of the year. The stock has more than doubled in the last 12 months.
No comments:
Post a Comment